2022;14(2):e1540
& Lord, C
SURMOUNT-1 demonstrated 15%, 19.5%, and 20.9% body weight reduction at 5, 10, and 15 mg respectively over 72 weeks FDA approvals : Mounjaro (T2D, May 2022) and Zepbound (obesity, November 2023) Cardiovascular outcomes : SURPASS-CVOT in progress to evaluate cardiovascular safety and efficacy Global availability : Approved in US, EU, and numerous international markets Side Effects and Safety Comparison# Mazdutide Side Effects# GI effects : Nausea, diarrhea, and vomiting consistent with GLP-1 class
Glutathione helps regulate this balance by controlling the activation and suppression of immune cells
demonstrated that combined GHRH + GHRP administration produced 2 to 3 times more GH release than either compound individually in healthy subjects (Anderson et al., J Clin Endocrinol Metab 2001)
Recently, trigger points have been implicated in various conditions, including myofascial pain syndrome (a chronic disorder involving the muscles and the surrounding connective tissue)